Moderna Shares Jump 13% on New Autoimmune Disease Treatment Push

Moderna (MRNA) shares rose 13% on Friday after the biotechnology company revealed a new effort to develop a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond COVID-19 vaccines in coming years.

The Product

Moderna announced a new research program targeting autoimmune disease treatments, without providing specific details on compounds or mechanisms. The company also outlined plans to develop several experimental drugs in other therapeutic areas to reduce reliance on COVID-19 vaccines.

Pricing and Availability

Moderna has not yet disclosed any pricing details or expected timelines for the treatment's availability, as the project remains in early research and development stages.

Competition

Moderna faces intense competition in the autoimmune disease treatment space from companies such as AbbVie, Johnson & Johnson, and Novartis, which already have approved therapies. However, Moderna's mRNA technology could give it a competitive edge in developing novel treatments.

Potential Impact on the Company

This announcement represents a key strategic move for Moderna to diversify its revenue streams, especially as demand for COVID-19 vaccines declines. If successful, these efforts could open up large new markets, but they are still in very early stages and carry typical development risks.